Brokerage Firm Rating on VIVUS (VVUS)

VIVUS (VVUS) has an average broker rating of 2.75, which is interpreted as a Hold, as rated by 4 equity analysts. Nonetheless, 1 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. Nevertheless, the majority of 2 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 1, which is also a Strong Buy. 1 considers that the stock is a Sell.


Company shares have received an average consensus rating of Hold for the current week VIVUS (NASDAQ:VVUS): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $1.06 and $1.05 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $1.10. The buying momentum continued till the end and the stock did not give up its gains. It closed at $1.08, notching a gain of 1.89% for the day. The total traded volume was 327,492 . The stock had closed at $1.06 on the previous day.

In a related news,The officer (Chief Medical Officer) of Vivus Inc, Varghese Santosh T sold 12,559 shares at $1.07 on August 2, 2016. The Insider selling transaction had a total value worth of $13,438. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.

VIVUS, Inc. is a biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutic products. It provides two therapies approved by the Food and Drug Association (FDA), which include Qsymia (phentermine and topiramate extended-release) for chronic weight management and STENDRA (avanafil) for erectile dysfunction (ED). The Company is also developing and has completed the Phase II studies of Qsymia for the indication of OSA and diabetes. Qsymia is available in over 42,000 certified retail pharmacies across the country. STENDRA is also approved by the European Commission (EC), under the name, SPEDRA, for the treatment of ED in the Europe. As of September 18, 2014, the FDA approved a Supplemental New Drug Application (sNDA) for STENDRA. STENDRA is indicated to be taken approximately 15 minutes before sexual activity.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.